FDA Still Needs Convincing On Use Of Non-Inferiority Trials For CAP – Temple
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Industry has provided little data supporting the use of non-inferiority trials as the basis for approval for community-acquired pneumonia, FDA Office of Medical Policy Director Bob Temple said at a recent workshop on clinical trial design for CAP
You may also be interested in...
FDA Panel Offers Specifics For Revised CAP Trial Guidance, No Big Changes
Advisory committee proposes a 10% non-inferiority margin for community-acquired pneumonia drugs. The Anti- Infective Drugs panel agreed that it is possible to establish a treatment effect for comparator agents based on incomplete data from original placebocontrolled CAP trials of the early 1900s. However, the group was divided over whether there is a basis for evaluating endpoints other than mortality. There was consensus that placebo-controlled trials are inappropriate for any severity of CAP
Otitis Media Studies Can Use Four Trial Designs Under FDA Draft Guidance
FDA's draft guidance for developing drugs to treat acute bacterial otitis media offers sponsors four possible superiority study designs